» Articles » PMID: 11861647

Glycogen Synthase Kinase-3 Beta Mutagenesis Identifies a Common Binding Domain for GBP and Axin

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Feb 28
PMID 11861647
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Glycogen synthase kinase-3 beta (GSK-3) is a key downstream target of Wnt signaling and is regulated by its interactions with activating and inhibitory proteins. We and others have shown that GSK-3 activity toward non-primed substrates is regulated in part through a competition between its activating (Axin) and inhibitory (GBP/FRAT) binding partners. Here we use a reverse two-hybrid screen to identify mutations in GSK-3 that alter binding to GBP and Axin. We find that these mutations overlap and propose that GBP and Axin compete for binding to the same region of GSK-3. We use these mutations to examine the ability of GSK-3 to block eye development in Xenopus embryos and suggest that GSK-3 regulates eye development through a non-Wnt pathway.

Citing Articles

GSK3α, not GSK3β, drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring.

Draffin J, Sanchez-Castillo C, Fernandez-Rodrigo A, Sanchez-Saez X, Avila J, Wagner F EMBO J. 2020; 40(2):e105513.

PMID: 33197065 PMC: 7809792. DOI: 10.15252/embj.2020105513.


Jmjd6a regulates GSK3β RNA splicing in Xenopus laevis eye development.

Shin J, Son J, Kim W, Gwak J, Ju B PLoS One. 2019; 14(7):e0219800.

PMID: 31361752 PMC: 6667200. DOI: 10.1371/journal.pone.0219800.


A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.

Kakade V, Tao S, Rajagopal M, Zhou X, Li X, Yu A J Mol Cell Biol. 2016; 8(6):464-476.

PMID: 27190311 PMC: 5181316. DOI: 10.1093/jmcb/mjw022.


Overexpression of FRAT1 is associated with malignant phenotype and poor prognosis in human gliomas.

Guo G, Zhong C, Liu Y, Mao X, Zhang Z, Jin J Dis Markers. 2015; 2015:289750.

PMID: 25922553 PMC: 4398933. DOI: 10.1155/2015/289750.


Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Beurel E, Grieco S, Jope R Pharmacol Ther. 2014; 148:114-31.

PMID: 25435019 PMC: 4340754. DOI: 10.1016/j.pharmthera.2014.11.016.